Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key HIV Studies Influencing My Practice Following IDWeek 2021 – Audio Recap

Source: IDWeek 2021: Clinical Impact of New Data*
September 29 - October 3, 2021; Virtual
Listen to expert insights from Darcy Wooten, MD, on updates and new HIV data from IDWeek 2021, including 2-drug ART, metabolic outcomes, investigational agents, and survey data of the U=U educational campaign.
Darcy Wooten, MD
Released: October 11, 2021

In this episode, Darcy Wooten, MD, discusses new HIV data from IDWeek 2021, including:

  • A rapid test-and-treat program to start DTG/3TC in patients newly diagnosed with HIV (STAT)
  • Efficacy when switching from 3-drug to 4-drug TAF-based regimens to DTG/3TC (TANGO)
  • Virologic outcomes with 2-drug vs 3-drug ART regimens (Trio Health HIV Network Study)
  • Metabolic complications in treatment-naive patients (Study 1489 and Study 1490)
  • Resistance analysis of an investigational agent, lenacapavir (CALIBRATE)
  • The Positive Perspectives Survey to evaluate the U=U Educational Campaign in North American patients

Information on this Educational Activity

Faculty

Darcy Wooten, MD

Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California

Darcy Wooten, MD, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Expert recap of new data on HIV drug resistance from EACS 2021, from Dr Babafemi Taiwo and Clinical Care Options (CCO)

Babafemi Taiwo, MBBS Released: November 23, 2021

Prof. Don Smith addresses what healthcare professionals in Australia need to know about long-acting antiretroviral agents, from Clinical Care Options (CCO)

Prof. Don Smith Released: November 23, 2021

Dr Roger Bedimo discusses the need for prophylaxis for Pneumocystis jirovecii pneumonia in virologically suppressed patients, from Clinical Care Options (CCO)

Roger Bedimo, MD, MS, FACP Released: November 23, 2021

Clinical Care Options (CCO) expert analysis of new data from EACS 2021, provided by expert HIV faculty

person default Tristan J. Barber, MA, MD, FRCP Released: November 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue